New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:52 EDTREGNRegeneron upgraded to Buy from Neutral at Citigroup
Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:51 EDTREGNBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:31 EDTREGNRegeneron price target raised to $462 from $418 at BofA/Merrill
Subscribe for More Information
November 20, 2014
07:47 EDTREGNRegeneron price target raised to $450 from $390 at Brean Capital
Subscribe for More Information
05:22 EDTREGNRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
08:17 EDTREGNRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
November 18, 2014
05:43 EDTREGNRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use